Bicara CEO sells 8,234 shares after option exercise

Bicara Therapeutics director and Chief Executive Officer Claire Mazumdar reported a series of option exercises and related share sales.

Rhea-AI Filing Summary

Bicara Therapeutics director and Chief Executive Officer Claire Mazumdar reported a series of option exercises and related share sales. Over March 4–6, 2026, she exercised stock options to acquire a total of 8,234 shares of common stock at an exercise price of $3.7898 per share.

On each day, the same number of shares was sold in open‑market transactions, totaling 8,234 shares sold at weighted average prices around $18.73–$18.92. These transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 12, 2025. Following these trades, Mazumdar directly owned 339,392 shares of common stock and held 233,476 stock options.

Insider Trade Summary

Exercise and Sale: 8,234 shares ($123K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Mazumdar Claire

Role Chief Executive Officer

Sold 8,234 shs ($154K)

Approx. gross sale proceeds $154K

Approx. exercise cost $31K

Approx. pre-tax spread $123K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,817	$0.00	$0.00
Exercise	Common Stock	3,817	$3.7898	$14K
Sale	Common Stock	3,817	$18.7508	$72K
Exercise	Stock Option (Right to Buy)	1,786	$0.00	$0.00
Exercise	Common Stock	1,786	$3.7898	$7K
Sale	Common Stock	1,786	$18.7369	$33K
Exercise	Stock Option (Right to Buy)	2,631	$0.00	$0.00
Exercise	Common Stock	2,631	$3.7898	$10K
Sale	Common Stock	2,631	$18.7338	$49K

Holdings After Transaction: Stock Option (Right to Buy) — 227,873 contracts (Direct); Common Stock — 339,392 shares (Direct)

Footnotes (5)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. F5. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BCAX CEO Claire Mazumdar report?

Claire Mazumdar reported exercising stock options and selling the resulting shares. From March 4–6, 2026, she exercised options for 8,234 Bicara Therapeutics shares at $3.7898 and sold the same 8,234 shares in open‑market transactions at weighted average prices between about $18.73 and $18.92.

How many Bicara Therapeutics (BCAX) shares did the CEO sell?

The CEO sold 8,234 shares of Bicara Therapeutics common stock. These sales occurred over three days, March 4–6, 2026, in multiple open‑market transactions, at reported weighted average prices ranging approximately from $18.73 to $18.92 per share, according to the Form 4 filing.

Were the BCAX insider sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed under a Rule 10b5‑1 trading plan. That plan was adopted on February 12, 2025, providing a pre‑arranged schedule for trades, which allows executives to systematically sell shares according to preset instructions.

What is the option exercise price for the BCAX CEO’s stock options?

The reported option exercise price is $3.7898 per share. Over March 4–6, 2026, Claire Mazumdar exercised stock options at this price to acquire 8,234 Bicara Therapeutics common shares, which were then sold in separate open‑market transactions at significantly higher weighted average prices.

How many BCAX shares does the CEO own after these transactions?

After the reported trades, Claire Mazumdar directly owned 339,392 Bicara Therapeutics common shares. The Form 4 also shows she held 233,476 stock options following the latest option exercises, reflecting both her current equity stake and remaining option-based compensation position.

Over what price ranges were the BCAX insider sales executed?

The filing reports weighted average sale prices with defined ranges. The shares were sold in multiple trades at prices ranging from $18.73 up to between $18.77, $18.795, and $18.92 per share, depending on the specific transaction batch, as detailed in the Form 4 footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 07:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M(1)		2,631	A	$3.7898	342,023	D
Common Stock	03/04/2026		S(1)		2,631	D	$18.7338(2)	339,392	D
Common Stock	03/05/2026		M(1)		1,786	A	$3.7898	341,178	D
Common Stock	03/05/2026		S(1)		1,786	D	$18.7369(3)	339,392	D
Common Stock	03/06/2026		M(1)		3,817	A	$3.7898	343,209	D
Common Stock	03/06/2026		S(1)		3,817	D	$18.7508(4)	339,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	03/04/2026		M(1)			2,631	(5)	08/08/2033	Common Stock	2,631	$0	233,476	D
Stock Option (Right to Buy)	$3.7898	03/05/2026		M(1)			1,786	(5)	08/08/2033	Common Stock	1,786	$0	231,690	D
Stock Option (Right to Buy)	$3.7898	03/06/2026		M(1)			3,817	(5)	08/08/2033	Common Stock	3,817	$0	227,873	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.